Forget Meme Stocks and Bitcoin. These Investors Are Hunting Quality.

After an everything rally that pushed major stock indexes near new highs, some investors just want…

Johnson & Johnson to Acquire Cancer-Treatment Developer Amrbx for $2B

Johnson & Johnson will acquire cancer-treatment developer Ambrx Biopharma in a $2 billion cash deal. The…

Johnson & Johnson to Acquire Cancer-Treatment Developer Amrbx for $2 Billion

Johnson & Johnson will acquire cancer-treatment developer Ambrx Biopharma in a $2 billion cash deal. The…

Investors Hope the Dogs of the Dow Can Find Their Bite

The Dogs of the Dow weren’t the best in show last year, but the recent rally…

A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?

In pharma, you can take a larger slice of the healthcare pie than your peers, but…

Nasdaq Set to Beat NYSE in IPO Race for Fifth Year in a Row

Nasdaq is on track to beat the New York Stock Exchange in the battle for initial…

Microsoft Tops the List of Best-Managed Companies of 2023

Journal Reports: Leadership What’s New in the Best Managed Companies Rankings in 2023 By Rick Wartzman…

Bond Yields Hit Fresh Multiyear Highs After Hot Retail Sales Data

U.S. government bond yields hit fresh decade-plus highs Tuesday after another hot economic-data release fueled concerns…

Blockbuster Cancer Treatment Stymied by Supply Chain—for Now

A cell therapy for multiple myeloma promises to be a major blockbuster for J&J and partner…

Big Pharma’s Battle With the Biden Administration Could Have Legs

Wall Street should pay attention as the pharma industry mounts a widening legal campaign against the…